OXcan creates cutting edge new innovations using rigorous scientific approaches
Our scientists have decades of experience in cancer biomarker discovery, machine learning, proteomics, and genomics
High throughput multi-omics with an emphasis on proteins to discover previously unknown biomarkers for unprecedented cancer early detection accuracy
We develop proprietary state-of-the-art machine learning approaches tailored to maximising modern clinical and high throughput data potential
Our machine learning approaches address key challenges associated with achieving successful cancer detection using liquid biopsy data
Robust feature selection for high dimensional data
Solution for analysing data with class imbalance
Integration of multi-omics interactions
Biological expertise informed algorithms
Combining advanced mass spectrometry proteomics with tailored machine learning analysis, our scientific team works with leading experts to discover effective composite biomarkers for cancer management.
State of art multi-omic liquid biopsy analysis with a focus on proteomics
Proprietary machine learning approaches to maximise liquid biopsy and high dimensional clinical data potential
Feature selection of succinct biomarker panel for cancer detection
Readily implementable tests using standard and approved clinical laboratory procedures
Transformative innovations for cancer management
%20(1).svg)
